Using EEG-Guided Basket and Umbrella Trials in Psychiatry: A Precision Medicine Approach for Cognitive Impairment in Schizophrenia

Due to advances over the last several decades, many fields of medicine are moving toward a precision medicine approach where treatments are tailored to nuanced patient factors. While in some disciplines these innovations are commonplace leading to unique biomarker-guided experimental medicine trials...

Full description

Bibliographic Details
Main Authors: Yash B. Joshi, Gregory A. Light
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-11-01
Series:Frontiers in Psychiatry
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fpsyt.2018.00554/full
id doaj-029c1d88dd9e4f6ba79b34108887d92b
record_format Article
spelling doaj-029c1d88dd9e4f6ba79b34108887d92b2020-11-24T21:47:47ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402018-11-01910.3389/fpsyt.2018.00554416872Using EEG-Guided Basket and Umbrella Trials in Psychiatry: A Precision Medicine Approach for Cognitive Impairment in SchizophreniaYash B. Joshi0Gregory A. Light1Gregory A. Light2Department of Psychiatry, University of California, San Diego, La Jolla, CA, United StatesDepartment of Psychiatry, University of California, San Diego, La Jolla, CA, United StatesVISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Health Care System, San Diego, CA, United StatesDue to advances over the last several decades, many fields of medicine are moving toward a precision medicine approach where treatments are tailored to nuanced patient factors. While in some disciplines these innovations are commonplace leading to unique biomarker-guided experimental medicine trials, there are no such analogs in psychiatry. In this brief review, we will overview two unique biomarker-guided trial designs for future use in psychiatry: basket and umbrella trials. We will illustrate how such trials could be useful in psychiatry using schizophrenia as a candidate illness, the EEG measure mismatch negativity as the candidate biomarker, and cognitive impairment as the target disease dimension.https://www.frontiersin.org/article/10.3389/fpsyt.2018.00554/fullschizophreniamismatch negativitybiomarkerclinical trialcognitive impairment
collection DOAJ
language English
format Article
sources DOAJ
author Yash B. Joshi
Gregory A. Light
Gregory A. Light
spellingShingle Yash B. Joshi
Gregory A. Light
Gregory A. Light
Using EEG-Guided Basket and Umbrella Trials in Psychiatry: A Precision Medicine Approach for Cognitive Impairment in Schizophrenia
Frontiers in Psychiatry
schizophrenia
mismatch negativity
biomarker
clinical trial
cognitive impairment
author_facet Yash B. Joshi
Gregory A. Light
Gregory A. Light
author_sort Yash B. Joshi
title Using EEG-Guided Basket and Umbrella Trials in Psychiatry: A Precision Medicine Approach for Cognitive Impairment in Schizophrenia
title_short Using EEG-Guided Basket and Umbrella Trials in Psychiatry: A Precision Medicine Approach for Cognitive Impairment in Schizophrenia
title_full Using EEG-Guided Basket and Umbrella Trials in Psychiatry: A Precision Medicine Approach for Cognitive Impairment in Schizophrenia
title_fullStr Using EEG-Guided Basket and Umbrella Trials in Psychiatry: A Precision Medicine Approach for Cognitive Impairment in Schizophrenia
title_full_unstemmed Using EEG-Guided Basket and Umbrella Trials in Psychiatry: A Precision Medicine Approach for Cognitive Impairment in Schizophrenia
title_sort using eeg-guided basket and umbrella trials in psychiatry: a precision medicine approach for cognitive impairment in schizophrenia
publisher Frontiers Media S.A.
series Frontiers in Psychiatry
issn 1664-0640
publishDate 2018-11-01
description Due to advances over the last several decades, many fields of medicine are moving toward a precision medicine approach where treatments are tailored to nuanced patient factors. While in some disciplines these innovations are commonplace leading to unique biomarker-guided experimental medicine trials, there are no such analogs in psychiatry. In this brief review, we will overview two unique biomarker-guided trial designs for future use in psychiatry: basket and umbrella trials. We will illustrate how such trials could be useful in psychiatry using schizophrenia as a candidate illness, the EEG measure mismatch negativity as the candidate biomarker, and cognitive impairment as the target disease dimension.
topic schizophrenia
mismatch negativity
biomarker
clinical trial
cognitive impairment
url https://www.frontiersin.org/article/10.3389/fpsyt.2018.00554/full
work_keys_str_mv AT yashbjoshi usingeegguidedbasketandumbrellatrialsinpsychiatryaprecisionmedicineapproachforcognitiveimpairmentinschizophrenia
AT gregoryalight usingeegguidedbasketandumbrellatrialsinpsychiatryaprecisionmedicineapproachforcognitiveimpairmentinschizophrenia
AT gregoryalight usingeegguidedbasketandumbrellatrialsinpsychiatryaprecisionmedicineapproachforcognitiveimpairmentinschizophrenia
_version_ 1725895616347766784